{
    "summary": "The Biosimilar Red Tape Elimination Act (H.R. 5526) aims to streamline the process for determining the interchangeability of biosimilar biological products with their reference products. The bill amends Section 351(k) of the Public Health Service Act, removing or modifying requirements related to interchangeable status determination, updating guidance from the Secretary, and clarifying timing for deemed interchangeability. The goal is to improve the regulatory framework for biosimilars.",
    "tags": [
        "Healthcare",
        "Consumer protection",
        "Technology regulation",
        "Healthcare access"
    ],
    "category": "Healthcare & Public Health"
}